Pfizer and DNDi Advancing International Research Efforts in The Fight Against Neglected Tropical Diseases

[New York, USA, Geneva, Switzerland – November 18, 2009]
Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.

Eisai and DNDi Enter into a Collaboration and License Agreement To Develop a New Drug for Chagas Disease

[Geneva, Switzerland – September 29, 2009]
Eisai Co., Ltd. (“Eisai”) and the Drugs for Neglected Diseases initiative (DNDi), a non-profit independent foundation, announced today that they have signed a collaboration and license agreement for the clinical development of a promising new drug for the treatment of Chagas disease, a fatal infectious disease that threatens 100 million people in Latin America and the Caribbean.
[Español] [Português]

Sanofi et DNDi – Drugs for Neglected Diseases initiative – signent un accord innovant pour la recherche de nouveaux médicaments contre les maladies tropicales négligées

[Paris, France et Genève, Suisse – Le 30 mai 2011]
Sanofi (EURONEXT : SAN et NYSE : SNY) et la Drugs for Neglected Diseases initiative (DNDi) annoncent aujourd’hui la signature d’un accord de collaboration de trois ans pour la recherche de nouveaux traitements contre neuf maladies tropicales négligées, définies par l’Organisation mondiale de la Santé (OMS) et nécessitant de toute urgence le développement de nouveaux traitements, adaptés et efficaces pour traiter les patients des  pays endémiques. Cet accord s’appuie sur des liens étroits et fructueux qui unissent de longue date Sanofi et DNDi.
[English]

New Consortium to Develop Drugs for Neglected Tropical Diseases

[Leiden, The Netherlands – August 17, 2009]
PRNewswire – A new consortium has been formed to boost drug development for the treatment of two deadly diseases, African sleeping sickness and Leishmaniasis, which affect millions of people worldwide. A total budget of nearly 3.6 million euros has been allocated over the next 4 years, to develop effective drugs for these diseases. The consortium includes IOTA Pharmaceuticals, Mercachem, Nycomed, the Drugs for Neglected Diseases initiative, the Royal Tropical Institute, the University of Bern, the VU University Amsterdam and TI Pharma.
[English] [Deutsch]

La organización internacional Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi), el Centro de Investigación en Salud Internacional de Barcelona y la Fundación Clínic para la Investigación Biomèdica aunarán esfuerzos en la investigación para luchar contra la Enfermedad de Chagas

[Ginebra, Suiza/Barcelona, España15 de marzo de 2010]
Hoy tendrá lugar en Barcelona, la firma del convenio de colaboración entre Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi), a través de su Director Ejecutivo el Dr. Bernard Pècoul, el Centro de Investigación en Salud Internacional de Barcelona (CRESIB, Hospital Clínic-Universidad de Barcelona), a través de su director el Dr. Pedro L. Alonso, y la Fundación Clínic para la Investigación Biomédica (FCRB), a través de su director el Sr. Emili Bargalló.
[English]

La organización internacional Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi), el Centro de Investigación en Salud Internacional de Barcelona y la Fundación Clínic para la Investigación Biomèdica aunarán esfuerzos en la investigación para luchar contra la Enfermedad de Chagas

[Ginebra, Suiza/Barcelona, España15 de marzo de 2010]
Hoy tendrá lugar en Barcelona, la firma del convenio de colaboración entre Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi), a través de su Director Ejecutivo el Dr.  Bernard Pècoul, el Centro de Investigación en Salud Internacional de Barcelona (CRESIB, Hospital Clínic-Universidad de Barcelona), a través de su director el Dr. Pedro L. Alonso, y la Fundación Clínic para la Investigación Biomédica (FCRB), a través de su director el Sr. Emili Bargalló.
[English]

Eisai y DNDi firman un contrato de colaboración para desarrollar un nuevo medicamento contra el mal de Chagas

[29 de Septiembre de 2009, Tokio, Japón y Ginebra, Suiza]
Eisai Co., Ltd. (“Eisai”) y la iniciativa Medicamentos para Enfermedades Olvidadas (DNDi, en sus siglas en inglés), una fundación independiente sin fines lucrativos, han anunciado hoy su contrato de colaboración para el desarrollo clínico de un nuevo y prometedor medicamento para el tratamiento de pacientes con mal de Chagas, una enfermedad infecciosa letal que amenaza a 100 millones de personas en América Latina y el Caribe.
[English]
[Português]

Eisai e DNDi iniciam Acordo de Colaboração e Licenciamento para desenvolver novo medicamento contra a doença de Chagas

[29 de setembro de 2009, Tóquio, Japão e Genebra, Suíça]
Eisai Co., Ltd. (“Eisai”) e a iniciativa Medicamentos para Doenças Negligenciadas (DNDi), uma fundação independente sem fins lucrativos, anunciaram hoje a assinatura de um acordo de colaboração para o desenvolvimento clínico de um novo e promissor medicamento para o tratamento de pacientes com a doença de Chagas, uma doença infecciosa fatal que ameaça 100 milhões de pessoas na América Latina e no Caribe.
[English] [Español]

Eisai e DNDi iniciam Acordo de Colaboração e Licenciamento para desenvolver novo medicamento contra a doença de Chagas

[29 de setembro de 2009, Tóquio, Japão e Genebra, Suíça]
Eisai Co., Ltd. (“Eisai”) e a Iniciativa Medicamentos para Doenças Negligenciadas (DNDi), uma fundação independente sem fins lucrativos, anunciaram hoje a assinatura de um acordo de colaboração para o desenvolvimento clínico de um novo e promissor medicamento para o tratamento de pacientes com a doença de Chagas, uma doença infecciosa fatal que ameaça 100 milhões de pessoas na América Latina e no Caribe.
[English] [Español]

Progress in Africa on medical R&D – from patient needs to new treatments

[Nairobi, KenyaJune 23, 2009]
Over 250 African and international health researchers, policymakers and three Ministers of Health (Kenya, Sudan, and Uganda) from 28 countries are meeting today in Nairobi at the 2nd international Drugs for Neglected Diseases initiative (DNDi) stakeholder conference organised to stimulate greater regional research partnership to fight the most neglected diseases such as sleeping sickness, kala azar, malaria, and Chagas disease.

Drug Discovery Unit, University of Dundee, and DNDi Collaborate to Identify Drug Candidates to Treat Visceral Leishmaniasis

[ Dundee, UK, and Geneva, Switzerland June 22, 2009 ]
On the eve of an international meeting bringing together 200 African researchers to discuss progress on research for neglected tropical diseases (NTD), the Drug Discovery Unit University of Dundee, and Drugs for Neglected Diseases initiative (DNDi) announced today that they have initiated a collaboration on the discovery and development of affordable and effective therapies for visceral leishmaniasis (kala azar).

Merck & Co., Inc. and Drugs for Neglected Diseases initiative Collaborate to Find Treatments

[Nairobi, Kenya, and Whitehouse Station, N.J., USAJune 22, 2009]
On the eve of an international meeting bringing together 200 African researchers to discuss progress on research for neglected tropical diseases (NTD), Merck & Co., Inc. and the not-for-profit Drugs for Neglected Diseases initiative (DNDi) announced a master agreement to support discovery and development of improved treatments for NTDs.

TB Alliance and DNDi Announce Collaborations with Anacor to Apply Boron Technology to Identify New Medicines for Neglected Diseases

[ Palo Alto, Calif., New York, NY and Geneva, Switzerland May 27, 2009 ]
Anacor Pharmaceuticals today announced that it has entered into a license and research agreement with not-for-profit Global Alliance for TB Drug Development (TB Alliance) to explore a novel anti-bacterial drug target for use in tuberculosis (TB) therapy.  Under the agreement, Anacor will provide the TB Alliance with a non-exclusive, royalty-free worldwide license for TB.

Sanofi-aventis et DNDi signent un accord de collaboration pour un nouveau médicament dans la maladie du sommeil, le fexinidazole

[ Paris, France, et Genève, Suisse – 18 mai 2009 ]
Sanofi-aventis (EURONEXT: SAN et NYSE : SNY) et la fondation Drugs for Neglected Diseases initiative (DNDi) annoncent aujourd’hui la signature d’un accord pour le développement, la fabrication, et la distribution du fexinidazole, un nouveau médicament prometteur pour le traitement de la Trypanosomiase Humaine Africaine ou maladie du sommeil, une maladie mortelle qui menace 60 millions de personnes en Afrique subsaharienne.
[English]

Sanofi-aventis et DNDi signent un accord de collaboration pour un nouveau médicament dans la maladie du sommeil, le fexinidazole

[ Paris, France, et Genève, Suisse – 18 mai 2009 ]
Sanofi-aventis (EURONEXT: SAN et NYSE : SNY) et la fondation Drugs for Neglected Diseases initiative (DNDi) annoncent aujourd’hui la signature d’un accord pour le développement, la fabrication, et la distribution du fexinidazole, un nouveau médicament prometteur pour le traitement de la Trypanosomiase Humaine Africaine ou maladie du sommeil, une maladie mortelle qui menace 60 millions de personnes en Afrique subsaharienne.
[English]